7-氯噻吩并[3,2-b]吡啶 | 69627-03-8

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 中文名称: 7-氯噻吩并[3,2-b]吡啶
• 中文别名: 7-氯噻酚[3,2-b]吡啶；7-氯噻吩[3,2-B]吡啶；7-氯-[3,2,b]-噻吩并吡啶；7-氯噻吩{3,2-B}吡啶
• 英文名称: 7-chlorothieno[3,2-b]pyridine
• 英文别名: 7-chlorothieno<3,2-b>pyridine
• CAS: 69627-03-8
• 化学式: C₇H₄ClNS
• mdl: MFCD08448161
• 分子量: 169.634
• InChiKey: GYQUXKQLCNFKQT-UHFFFAOYSA-N

物化性质

• 熔点：
  34.0-35.5 °C
• 沸点：
  257.5±20.0 °C(Predicted)
• 密度：
  1.435±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  0-10°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 7-Chlorothieno[3,2-b]pyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 7-Chlorothieno[3,2-b]pyridine
CAS number: 69627-03-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H4ClNS
Molecular weight: 169.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用

7-氯噻吩-{3,2-B}吡啶是一种吡啶类衍生物，可用作医药中间体。

反应信息

• 作为反应物：
  描述：

  7-氯噻吩并[3,2-b]吡啶 在 四(三苯基膦)钯 、 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 、 叔丁醇 为溶剂， 反应 63.3h， 生成 [2-(3-Methyl-3H-imidazol-4-yl)-thieno[3,2-b]pyridin-7-yl]-(2-methyl-1H-indol-5-yl)-amine
  参考文献：
  名称：

  大规模制备咪唑-噻吩并吡啶的交叉偶联方法：[2-(3-Methyl-3H-imidazol-4-yl)-thieno[3,2-b]pyridin-7-yl]-的合成(2-甲基-1H-吲哚-5-基)-胺

  摘要：

  [2-(3-methyl-3H-imidazol-4-yl)-thieno[3,2-b]pyridin-7-yl]-(2-methyl-1H-indol-5-yl)的数百克合成)-胺 (1) 描述了利用碘噻吩并吡啶 (3) 与 5-(三丁基甲锡烷基)-1-甲基咪唑 (11) 的 Stille 交叉偶联。评估了几种交叉偶联方法将噻吩并吡啶 3 转化为咪唑-噻吩并吡啶 2，但只有两种方法有效：Stille 偶联和源自 2-(叔丁基二甲基甲硅烷基)-1- 的有机锌试剂的 Negishi 交叉偶联甲基咪唑和碘噻吩并吡啶 (3)。后一种方法在实验室规模 (<50 g) 上运行良好，但在放大时反复无常。讨论了有机锡烷试剂放大的问题，包括有机锡水平的控制和分析。

  DOI：

  10.1021/op0340457
• 作为产物：
  描述：

  thieno<3,2-b>pyridine 4-oxide monohydrate 在 硫酸 、 硝酸 、 铁粉 、 乙酰氯 作用下， 以 溶剂黄146 为溶剂， 反应 7.5h， 生成 7-氯噻吩并[3,2-b]吡啶
  参考文献：
  名称：

  Klemm, L. H.; Louris, John N.; Boisvert, William, Journal of Heterocyclic Chemistry, 1985, vol. 22, p. 1249 - 1252

  摘要：

  DOI：
• 作为试剂：
  描述：

  7-氯噻吩并[3,2-b]吡啶 、 ((6-溴吡啶-3-基)甲基)(2-甲氧基乙基)氨基甲酸叔丁酯 在 7-氯噻吩并[3,2-b]吡啶 作用下， 以72的产率得到tert-butyl ((6-(7-chlorothieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)(2-methoxyethyl)carbamate
  参考文献：
  名称：

  Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors

  摘要：

  本发明涉及用于制造融合杂环型激酶抑制剂化合物的中间体，例如基于噻唑吡啶的化合物，特别是在工业水平上。

  公开号：

  US20130310564A1

文献信息

• [EN] BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE<br/>[FR] DERIVES D'AMIDE HETEROARYLE BENZOCONDENSE DE THIENOPYRIDINES UTILISEES EN TANT QU'AGENTS THERAPEUTIQUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCEDES D'UTILISATION ASSOCIES
  申请人：PFIZER

  公开号：WO2003106462A1

  公开（公告）日：2003-12-24

  The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.

  该发明涉及由公式I表示的化合物，以及这些化合物的前药或代谢物，或者这些化合物的药用可接受的盐或溶剂化合物，所述前药和代谢物，其中Z、Y、R11和R14、R15、R16和R17如本文所定义。该发明还涉及含有公式I化合物的药物组合物，以及通过给予公式I化合物来治疗哺乳动物的增殖过度性疾病的方法。
• Lewis Basic Salt-Promoted Organosilane Coupling Reactions with Aromatic Electrophiles
  作者：Tyler W. Reidl、Jeffrey S. Bandar

  DOI：10.1021/jacs.1c05764

  日期：2021.8.11

  Lewis basic salts promote benzyltrimethylsilane coupling with (hetero)aryl nitriles, sulfones, and chlorides as a new route to 1,1-diarylalkanes. This method combines the substrate modularity and selectivity characteristic of cross-coupling with the practicality of a base-promoted protocol. In addition, a Lewis base strategy enables a complementary scope to existing methods, employs stable and easily

  路易斯碱性盐促进苄基三甲基硅烷与（杂）芳基腈、砜和氯化物的偶联，作为制备 1,1-二芳基烷烃的新途径。该方法将交叉耦合的底物模块化和选择性特征与碱基促进协议的实用性结合起来。此外，路易斯碱策略能够对现有方法进行补充，采用稳定且易于制备的有机硅烷，并在酸性官能团存在下实现选择性芳基化。该方法的实用性通过药物类似物的合成及其在多组分反应中的应用得到证明。
• [EN] SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS D'HÉTÉROARYLE BICYCLIQUES SUBSTITUÉS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013049263A1

  公开（公告）日：2013-04-04

  Disclosed are azaindazole compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.

  披露了公式(I)的氮杂吲唑化合物：或其药用可接受盐，其中：X是O且Y是N；或者X是S且Y是CH；Z是CR2或N；Q是杂芳基；R1如本文所定义。还披露了使用这些化合物治疗至少一种与CYP17相关的病症的方法，例如，癌症，以及包含这些化合物的药物组合物。
• [EN] INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY<br/>[FR] INHIBITEURS D'ACTIVITÉ DE PROTÉINE TYROSINE KINASE
  申请人：METHYLGENE INC

  公开号：WO2009109035A1

  公开（公告）日：2009-09-11

  This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.

  本发明涉及抑制蛋白质酪氨酸激酶活性的化合物。特别是，本发明涉及抑制生长因子受体的蛋白质酪氨酸激酶活性的化合物，从而抑制受体信号传导，例如抑制VEGF受体信号传导。本发明还提供了用于治疗细胞增殖性疾病和状况以及眼科疾病、障碍和状况的化合物、组合物和方法。
• [EN] COMBINATION OF KINASE INHIBITORS AND USES THEREOF<br/>[FR] COMBINAISON D'INHIBITEURS DE KINASE ET SES UTILISATIONS
  申请人：INTELLIKINE LLC

  公开号：WO2014151147A1

  公开（公告）日：2014-09-25

  The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.

  本发明提供了一种治疗与受体内PI3-激酶α和/或mTOR相关的疾病状况的方法。另一方面，该发明提供了一种治疗与受体内PI3-激酶α和/或mTOR相关的疾病状况的方法。在另一个方面，提出了一种抑制细胞内Akt（S473）和Akt（T308）磷酸化的方法。本发明还提供了一种有效治疗与受体内PI3-激酶α和/或mTOR相关的疾病状况的药物套装。